[Immunocorrective therapy in esophageal cancer].
Additional non-specific therapy including levamisole and other drugs was tested in 20 patients with esophageal cancer. Complex (immuno- and chemoradiation) treatment brought immune response, lipid metabolism and cortisol level to normal, which in most cases, was in correlation with the clinical effect of therapy.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004338:Drug Combinations / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D014801:Vitamin A / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D004338:Drug Combinations; D014801:Vitamin A; D014810:Vitamin E; D007978:Levamisole; C048974:vitamin A, vitamin E drug combination
Immunokorrigiruiushchaia terapiia pri rake pishchevoda.